{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:55:46Z","timestamp":1760244946662},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Clin Pathol"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1309\/ajcpepx1c7hhfelk","type":"journal-article","created":{"date-parts":[[2009,12,19]],"date-time":"2009-12-19T00:53:00Z","timestamp":1261183980000},"page":"70-74","source":"Crossref","is-referenced-by-count":20,"title":["Aberrant Nuclear p53 Expression Predicts Hemizygous 17p (<i>TP53)<\/i>Deletion in Chronic Lymphocytic Leukemia"],"prefix":"10.1093","volume":"133","author":[{"given":"Hong","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan M.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connie X.Y.","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2010,1,1]]},"reference":[{"key":"2015120915243877000_133.1.70.1","doi-asserted-by":"crossref","unstructured":"Nigro JM Baker SJ Preisinger AC Mutations in the p53 gene occur in diverse human tumour types. Nature. 1987;342:705\u2013708.","DOI":"10.1038\/342705a0"},{"key":"2015120915243877000_133.1.70.2","unstructured":"Bartek J Bartkova J Vojtesek B Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 1991;6:1699\u20131703."},{"key":"2015120915243877000_133.1.70.3","unstructured":"Lepelley P Preudhomme C Vanrumbeke M Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia. 1994;8:1342\u20131349."},{"key":"2015120915243877000_133.1.70.4","doi-asserted-by":"publisher","DOI":"10.1038\/35094077"},{"key":"2015120915243877000_133.1.70.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.12.007"},{"key":"2015120915243877000_133.1.70.6","doi-asserted-by":"crossref","unstructured":"Villuendas R Piris MA Algara P The expression of p53 protein in non-Hodgkin\u2019s lymphomas is not always dependent on p53 gene mutations. Blood. 1993;82:3151\u20133156.","DOI":"10.1182\/blood.V82.10.3151.bloodjournal82103151"},{"key":"2015120915243877000_133.1.70.7","unstructured":"Cesarman E Inghirami G Chadburn A High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol. 1993;143:845\u2013856."},{"key":"2015120915243877000_133.1.70.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08911.x"},{"key":"2015120915243877000_133.1.70.9","doi-asserted-by":"crossref","unstructured":"Maestro R Gloghini A Doglioni C Human non-Hodgkin\u2019s lymphomas overexpress a wild-type form of p53 which is a functional transcriptional activator of the cyclin-dependent kinase inhibitor p21. Blood. 1997;89:2523\u20132528.","DOI":"10.1182\/blood.V89.7.2523"},{"key":"2015120915243877000_133.1.70.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"2015120915243877000_133.1.70.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-154070"},{"key":"2015120915243877000_133.1.70.12","doi-asserted-by":"crossref","unstructured":"Cordone I Masi S Mauro FR p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood. 1998;91:4342\u20134349.","DOI":"10.1182\/blood.V91.11.4342.411k39_4342_4349"},{"key":"2015120915243877000_133.1.70.13","unstructured":"Klobusick\u00e1 M Kusenda J Babus\u00edkov\u00e1 O . Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients. Neoplasma. 2002;49:387\u2013393."},{"key":"2015120915243877000_133.1.70.14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04306.x"},{"key":"2015120915243877000_133.1.70.15","unstructured":"Swerdlow SH Campo E Harris NL , eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008. WHO Classification of Tumours; vol 2."},{"key":"2015120915243877000_133.1.70.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(03)00217-6"},{"key":"2015120915243877000_133.1.70.17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200325"},{"key":"2015120915243877000_133.1.70.18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4723278.x"},{"key":"2015120915243877000_133.1.70.19","doi-asserted-by":"crossref","unstructured":"Lowe SW Sherr CJ . Tumor suppression by Ink4a-ARF: progress and puzzles. Curr Opin Genet Dev. 2002;13:77\u201383.","DOI":"10.1016\/S0959-437X(02)00013-8"},{"key":"2015120915243877000_133.1.70.20","unstructured":"Moll UM Petrenko O . The MDM2-p53 interaction. Mol Cancer Res. 2003;1:1001\u20131008."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajcp\/article-pdf\/133\/1\/70\/18132812\/ajcpath133-0070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T10:11:12Z","timestamp":1590315072000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article-lookup\/doi\/10.1309\/AJCPEPX1C7HHFELK"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1,1]]},"published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1309\/AJCPEPX1C7HHFELK"],"URL":"https:\/\/doi.org\/10.1309\/ajcpepx1c7hhfelk","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}